Clinical Trial

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Recruiting
View on ClinicalTrials.gov →
Summary
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2026-02-06
Trial Details
NCT Number NCT07143045
Lead Sponsor Alpha Biopharma (Jiangsu) Co., Ltd.
Conditions EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Enrollment 800 participants
Start Date 2025-12-29
Primary Completion 2031-05 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-09